Allergan and Ironwood Pharmaceuticals agreed to a settlement with Sun Pharma to resolve a patent dispute over the Indian company's abbreviated new drug application for a generic version of Linzess (linaclotide) in the U.S. The settlement, which will be subject to review by the U.S. Department of Justice and the Federal Trade Commission, will allow wholly-owned subsidiaries of Sun Pharma to seek a license to launch a generic version of Linzess in the U.S. beginning Feb. 1, 2031 -- or earlier, in certain circumstances -- and end the patent infringement litigation.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% |
|
+1.73% | +0.97% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,568 INR | +0.67% | +3.13% | 45.07B | ||
6.49 USD | +6.22% | -0.46% | 1.03B | ||
1st Jan change | Capi. | |
---|---|---|
+0.97% | 63.66B | |
+56.89% | 823B | |
+39.52% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.74% | 239B | |
+13.83% | 220B | |
-0.49% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- AGN Stock
- News Allergan plc
- Allergan and Ironwood Pharmaceuticals and Sun Pharma Reach Deal in Patent Dispute